Navigation Links
ARCALYST® (rilonacept) Meets Primary and All Secondary Endpoints in Second Phase 3 Trial for Prevention of Gout Flares in Patients Initiating Uric Acid-Lowering Therapy
Date:2/28/2011

he efficacy findings from the PRE-SURGE 1 trial demonstrating that treatment with ARCALYST reduced the incidence of such flares. With these positive Phase 3 trials in patients with gout initiating uric acid-lowering therapy, we plan to submit a supplemental Biologics License Application for U.S. regulatory approval in mid-2011."  

Regeneron also announced the results from a third Phase 3 study (RE-SURGE), which evaluated the safety of ARCALYST versus placebo over 16 weeks in 1,315 patients who were at risk for gout flares while initiating or taking uric acid-lowering drug treatment. In this study, ARCALYST® (rilonacept) was generally well tolerated, and the safety profile was consistent with that reported in the PRE-SURGE 1 and PRE-SURGE 2 studies.  Specifically, other than injection site reactions, the incidence of treatment-emergent adverse events was generally well-balanced among the 985 patients who received ARCALYST at a weekly, self-administered, subcutaneous dose of 160 mg and the 330 patients who received placebo.

In the RE-SURGE Phase 3 safety study, injection site reactions, usually considered mild, were reported more commonly with ARCALYST (15.2%) than with placebo (3.3%). Overall, the cumulative rate of infections was 20.1% in patients treated with ARCALYST and 19.1% in placebo patients.  Serious infections were reported in 0.5% of patients treated with ARCALYST and 0.9% of placebo patients. Deaths were reported for 0.3% of patients treated with ARCALYST and 0.9% of placebo patients.

In this safety study, efficacy was evaluated as a secondary endpoint, and all secondary endpoints were achieved. Compared to placebo, patients who received ARCALYST had a 71% decrease in mean number of patient-reported gout flares (p<0.0001). Compared to placebo, treatment with ARCALYST reduced the proportion of patients who reported at least one gout flare during the study period by 50% (p<0.0001) and reduced the proportion of
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Mindray Medical Meets 2010 Product Development Targets and Announces Strong 2011 Pipeline
2. New IonWorks Barracuda Automated Patch Clamp System Meets Need for Affordable, Accelerated Screening of Ligand- & Voltage-Gated Ion Channels Via Direct Electrophysiology Assays
3. US Oncology Meets With Leading Pharmaceutical and Biotech Companies to Design Clinical Trials for the Cancer Fighting Drugs of Tomorrow
4. LEO Pharmas PEP005 Meets Primary Endpoint in Phase III Trial for Pre-Cancerous Skin Condition
5. Poniard Pharmaceuticals Announces Phase 2 Trial of Picoplatin in Metastatic Colorectal Cancer Meets Primary Endpoint and Study Objectives
6. Investigational Sublingual Allergy Immunotherapy Tablet Meets Primary Endpoint in a Study of Adult Subjects With a History of Grass Pollen Allergies
7. Novartis drug Tasigna(R) meets primary endpoint in pivotal trial against Gleevec(R) as first-line treatment in chronic myeloid leukemia patients
8. Intercept Pharmaceuticals FXR Agonist INT-747 Meets Primary Endpoint in a Phase II Clinical Trial in Type 2 Diabetic Patients with Nonalcoholic Fatty Liver Disease
9. Jazz Pharmaceuticals and UCB Announce Second Phase III Study of Sodium Oxybate in Patients With Fibromyalgia Meets Primary Endpoints
10. MADIT-CRT Trial Meets Primary Endpoint
11. VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... MENLO PARK, Calif. , June 1, 2015 /PRNewswire/ ... medical device company that is providing innovative evidence-based solutions ... it has commenced an underwritten public offering of its ... by Nevro and 2,459,175 shares to be sold by ... grant the underwriters a 30-day option to purchase up ...
(Date:6/1/2015)... 2015 NEOVIA ONCOLOGY Ltd. http://www.neoviaoncology.com/ ... development and commercialization of novel, multi-function drugs for ... with the U.S. Food and Drug Administration (FDA) ... Investigational New Drug (IND) application for its lead ... the meeting, Neovia has clarified details of the ...
(Date:6/1/2015)... Novel t reatments   ... , says   GBI Research . ... will be driven primarily by the introduction of numerous premium ... either replace or combine with generic chemotherapies. Analysis ... Lung Cancer Market to 2020 - forecasts the value ...
Breaking Medicine Technology:Nevro Announces Proposed Public Offering of Common Stock 2Nevro Announces Proposed Public Offering of Common Stock 3Neovia Oncology Announces First IND Meeting 2New Therapies to Enhance Increasingly Competitive Non-Small Cell Lung Cancer Treatment Market 2New Therapies to Enhance Increasingly Competitive Non-Small Cell Lung Cancer Treatment Market 3
... ... 9 Reportlinker.com announces that a new market ... Atrial Fibrillation - Drug Pipeline Analysis and Market Forecasts ... Fibrillation - Drug Pipeline Analysis and Market Forecasts to ...
... , Feb. 9 Volcano Corporation (Nasdaq: ... therapy guidance tools designed to enhance the diagnosis and treatment ... has received 510(k) clearance from the U.S. Food and Drug ... catheter in the United States . This state-of-the-art catheter ...
Cached Medicine Technology:Reportlinker Adds Atrial Fibrillation - Drug Pipeline Analysis and Market Forecasts to 2016 2Reportlinker Adds Atrial Fibrillation - Drug Pipeline Analysis and Market Forecasts to 2016 3Reportlinker Adds Atrial Fibrillation - Drug Pipeline Analysis and Market Forecasts to 2016 4Reportlinker Adds Atrial Fibrillation - Drug Pipeline Analysis and Market Forecasts to 2016 5Reportlinker Adds Atrial Fibrillation - Drug Pipeline Analysis and Market Forecasts to 2016 6Reportlinker Adds Atrial Fibrillation - Drug Pipeline Analysis and Market Forecasts to 2016 7Reportlinker Adds Atrial Fibrillation - Drug Pipeline Analysis and Market Forecasts to 2016 8Volcano Receives FDA Clearance to Market the Eagle Eye(R) Platinum Digital IVUS Catheter 2Volcano Receives FDA Clearance to Market the Eagle Eye(R) Platinum Digital IVUS Catheter 3Volcano Receives FDA Clearance to Market the Eagle Eye(R) Platinum Digital IVUS Catheter 4
(Date:6/1/2015)... 2015 Cambia Health Solutions and ... new, interactive Affordable Care Act (ACA) training course ... called “Affordable Care Act Expert Series, Large Group ... and consultative insights necessary to effectively engage and ... impacts of the ACA. , The interactive, experience-based ...
(Date:6/1/2015)... a leading web-base electronic healthcare software (EHR) is providing ... Louisiana. The entrepreneurial trio behind Sharenote, will travel to ... with the tools and resources to monitor key performance ... , Find out why Sharenote is the EHR ... 250 practices. , Four Day Schedule , ...
(Date:6/1/2015)... Florida (PRWEB) June 01, 2015 KC ... generously donated $88,000 of the best superfood products ... the record-breaking floods in Texas. , "Monica and ... and Natural News in distributing Living Fuel Super Meals ... of the millennial floods in Texas," KC Craichy said. ...
(Date:6/1/2015)... More than 22 million children may miss out ... out and they lose access to free or reduced-price meal ... and milk companies are on a mission to bring more ... Milk Drive. , In many cases, food insecure children ... for the bulk of their daily nutrition. Although the National ...
(Date:6/1/2015)... (PRWEB) June 01, 2015 Northridge ... are now offering patients a promotion on Invisalign for ... of Invisalign treatment is reduced to $3,700. Patients can ... the complimentary consultation and discuss the extent of correction ... it cannot be combined with any other offer. ...
Breaking Medicine News(10 mins):Health News:Cambia Partners with AHIP to Offer Expert Series ACA Training Course 2Health News:Cambia Partners with AHIP to Offer Expert Series ACA Training Course 3Health News:Nearly $100,000 In Emergency Food Aid to Flood Victims in Texas Provided by Living Fuel and Natural News 2Health News:Nearly $100,000 In Emergency Food Aid to Flood Victims in Texas Provided by Living Fuel and Natural News 3Health News:Summer Nutrition Vital for Kids who Depend on Schools for Healthy Foods 2Health News:Northridge Dentists, Drs. Michel Elyson and Ramin Assili, are Now Offering a Limited Time Promotion on Invisalign 2
... , Desperate Housewives, Star Joins The ... Cancer Caregivers , , PHILADELPHIA, Sept. 14 ... TV show Desperate Housewives , found himself in a role ... The diagnosis of his two sisters in late 2008 left Chavira ...
... , , NCCN is holding ... to discuss the regulatory and operational aspects of research and ... can be made. Scheduled for October 26 - 27 in ... panel discussions on topics that challenge the conduct of oncology ...
... WEST PALM BEACH, Fla., Sept. 14 The Cosmetic ... New York (Oct 10th) is sold out. According to ... program, this is a reflection of the unmet educational ... and fellows in core esthetic specialties such as dermatology, ...
... BURLINGTON, Mass., Sept. 14 ClearPoint Metrics ... with the delivery of four new Compliance oriented Metrics ... Security Performance Manager (TM) and its compliance offering into ... and Compliance Manager. The new ClearPoint Compliance MAPS are ...
... , , ... 14 "The Dr. Oz Show," a high octane, multi-topic hour-long ... surgeon Dr. Mehmet Oz, premieres in syndication today (check local listings). ... the recently announced "Core Team Oz" guest contributors, fashion and style ...
... , , , ... , , SACRAMENTO, Calif., Sept. 14 ... and cough covering, healthy eating is a potent prevention method getting left ... eat a variety of healthy foods from all food groups throughout the ...
Cached Medicine News:Health News:Ricardo Antonio Chavira Uses Celebrity to Support Breast Cancer Caregivers 2Health News:Ricardo Antonio Chavira Uses Celebrity to Support Breast Cancer Caregivers 3Health News:Ricardo Antonio Chavira Uses Celebrity to Support Breast Cancer Caregivers 4Health News:NCCN Holds Oncology Research Best Practices Conference 2Health News:NCCN Holds Oncology Research Best Practices Conference 3Health News:ClearPoint Announces Metric Applications Packages for PCI DSS, NERC, Healthcare Compliance and FISMA 2Health News:ClearPoint Announces Metric Applications Packages for PCI DSS, NERC, Healthcare Compliance and FISMA 3Health News:ClearPoint Announces Metric Applications Packages for PCI DSS, NERC, Healthcare Compliance and FISMA 4Health News:'The Dr. Oz Show' Premieres Today Nationwide 2Health News:'The Dr. Oz Show' Premieres Today Nationwide 3Health News:'The Dr. Oz Show' Premieres Today Nationwide 4Health News:'The Dr. Oz Show' Premieres Today Nationwide 5Health News:Protect Your Family With Flu-Fighting Foods 2
Speculum with malleable plate to support flap during ablation of thestromal bed....
This adjustable lid speculum is angled 45 degrees and has 17 mm wire blades. It was designed to aspirate excess fluid around the eye during cataract and refractive procedures....
Adjustable wire speculum with 17 mm open blades. Lid tension adjustable throughout procedure with thumb screw control. Available with shaft straight or angled 45 degrees....
Open 13 mm blades. Screw-controlled locking mechanism. Dull finish....
Medicine Products: